This webinar on April 2 explored what biomarker discovery for cancer immunotherapy entails using high-dimensional multi-omic assays that can be difficult to interpret, particularly in the setting of challenging clinical trial designs such as small cohort size or unbalanced response rates. This webinar therefore addressed advances in computational science and biostatistics that allow for rigorous interpretation of complex exploratory biomarker data, when most studies are typically only powered for clinical endpoints. View the webinar for FREE on-demand HERE.